Vimarsana
Biggest News Aggregation in the World

Page 8 - Dose Management News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Management Today - Breaking & Trending Today

U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease - Vimarsana News

U.S. Veterans' Health Administration (VHA) provides coverage of LEQEMBI™ (lecanemab-irmb) for veterans living with early stages of Alzheimer's disease

Published: March 14, 2023

/PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing...

Source: prnewswire.com
Related Topics:
Uppsala LanOskar BossonUppsala UniversityVp CommunicationsNational Institutes Of HealthNational Institute OnMinistry Of HealthDrug AdministrationWashington University School Of MedicineUs Veterans Health AdministrationHealth AdministrationAlzheimer Network Trials UnitEuropean Medicines AgencyNational Medical Products AdministrationDevices AgencyAlzheimer Clinical Trial ConsortiumBiologics License ApplicationPriority ReviewPrescription Drug User Fee ActNew England JournalDose ManagementCarrier StatusAntithrombotic MedicationBrand NameMedical Devices Agency
U.S. VETERANS' HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI'S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER'S DISEASE - Vimarsana News

U.S. VETERANS' HEALTH ADMINISTRATION (VHA) PROVIDES COVERAGE OF LEQEMBI™ (LECANEMAB-IRMB) TWO MONTHS AFTER LEQEMBI'S FDA ACCELERATED APPROVAL FOR VETERANS LIVING WITH EARLY STAGES OF ALZHEIMER'S DISEASE

Published: March 13, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the U.S. Veterans' Health Administration (VHA) is...

Source: prnewswire.com
Related Topics:
New ZealandUnited KingdomHaruo NaitoLibby HolmanPrnewswire Eisai Co LtdCommunications DepartmentNational Institute OnMinistry Of HealthEisai Europe LtdPublic Relations DepartmentUs Veteran Health AdministrationNational Institutes Of HealthEisai IncDrug AdministrationWashington University School Of MedicineEisai Co LtdAlzheimer Network Trials UnitEuropean Medicines AgencyNational Medical Products AdministrationDevices AgencyAlzheimer Clinical Trial ConsortiumEarly StagesWill ContinueTransparently ShareHigh Quality Data
Biogen Inc.: FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease - Vimarsana News

Biogen Inc.: FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Published: March 6, 2023

Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with

Source: finanznachrichten.de
Related Topics:
New ZealandUnited KingdomUnited StatesDennis RiedlHaruo NaitoChristophera ViehbacherMike HenckeNatacha GassenbachLibby HolmanCommunications DepartmentInvestor Relations DepartmentNational Institute OnMinistry Of HealthEisai Europe LtdAdvisory CommitteeBiogen IncPublic Relations DepartmentNational Institutes Of HealthDrug AdministrationEisai IncWashington University School Of MedicineExchange CommissionEisai Co LtdAlzheimer Network Trials UnitEuropean Medicines Agency
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease - Vimarsana News

FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's Disease

Published: March 6, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

Source: prnewswire.com
Related Topics:
New ZealandUnited KingdomUnited StatesHaruo NaitoChristophera ViehbacherMike HenckeNatacha GassenbachLibby HolmanPrnewswire Eisai Co LtdCommunications DepartmentInvestor Relations DepartmentNational Institute OnMinistry Of HealthEisai Europe LtdAdvisory CommitteeBiogen IncPublic Relations DepartmentNational Institutes Of HealthDrug AdministrationEisai IncWashington University School Of MedicineExchange CommissionEisai Co LtdAlzheimer Network Trials UnitEuropean Medicines Agency
FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and gran - Vimarsana News

FDA accepts sBLA for traditional approval of LEQEMBI™ (lecanemab-irmb) for the treatment of Alzheimer's disease and gran

Published: March 6, 2023

STOCKHOLM, March 6, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

Source: europapress.es
Related Topics:
Uppsala LanOskar BossonUppsala UniversityVp CommunicationsNational Institutes Of HealthNational Institute OnMinistry Of HealthDrug AdministrationAdvisory CommitteeWashington University School Of MedicineAlzheimer Network Trials UnitEuropean Medicines AgencyNational Medical Products AdministrationDevices AgencyAlzheimer Clinical Trial ConsortiumNasdaq StockholmBiologics License ApplicationPriority ReviewPrescription Drug User Fee ActAccelerated Approval PathwayNew England JournalDose ManagementCarrier StatusAntithrombotic MedicationBrand Name